Investigating sirukumab for rheumatoid arthritis: 2-year results from the phase III SIRROUND-D study.

Sirukumab treatment resulted in sustained reductions in clinical signs and symptoms and minimal progression in radiographic damage over 2 years among patients with RA refractory to DMARDs. The safety profile of sirukumab was as expected for an anti-IL-6 agent, with no new signals reported.